API GMP Under ICH Q7
ICH Q7 sets the good manufacturing practice expectations for active pharmaceutical ingredients (APIs) — the substance that gives a drug product its therapeutic effect, manufactured before it is ever formulated into a tablet, injectable, or other dosage form. It applies GMP progressively across the synthetic or fermentation route, and it is the reference every API manufacturer, contract manufacturer, and finished-dose sponsor auditing its supply chain works from.
What an explainer is not
A topic explainer is SPEQ’s synthesis of what a practice involves, cited to the standards that govern it. It does not reproduce their text, and it does not determine which of them apply to your product or process.
[ POSITION IN THE FRAMEWORK ]
7 DIMENSIONS · 20 LINKSICH Q7 applies GMP that increases in stringency as synthesis approaches the active ingredient, so the argument a site must win is where its own controls start — not how tightly they are written.
06 · QUALITY MATURITY — API GMP UNDER ICH Q7, REACTIVE TO ADAPTIVE
Starting material designation was inherited from the supplier or the filing. Nobody at the site can say why GMP begins where it begins.
A designation rationale exists on paper, and steps downstream of it run under written procedures — but the synthetic route upstream is opaque and unaudited.
The designation is argued from the route: which steps affect impurity profile, which are purification points, and what the vendor is contractually bound to hold constant.
Route knowledge is maintained as the vendor changes: an upstream modification triggers reassessment of the designation itself, not only of the incoming specification.
Designation, route understanding and supplier oversight move together, so an API change is evaluated for where GMP should now begin rather than only for whether the spec still passes.
SPEQ’s shared five-stage progression, labelled synthesis — not the FDA QMM rating scale. Where does your organization sit? Score your quality system →
07 · REGULATORY & EVIDENCE
GOVERNING STANDARDS · 4
Derived from the 4 standards SPEQ maps to this subject, across 2 regulatory bodies: ICH, APIC.
RECORDS & OBJECTIVE EVIDENCE
- The API starting material designation with the synthetic route and the rationale supporting it
- Supplier qualification files for each step performed outside the site
- Process validation for the steps under the site’s own GMP, and the reprocessing or reworking provisions
- Impurity fate-and-purge reasoning across the route
- Batch records for the final purification and isolation steps, with in-process controls
COMMON INSPECTION FINDINGS
- A starting material designated by commercial convenience with no route-based justification
- Steps upstream of the designation performed by a vendor never audited against what they actually do
- Reprocessing performed routinely under a provision written for exceptional use
- Impurity carry-over from early steps never reasoned through to the final substance
- Route changes at the supplier absorbed as a specification update rather than assessed as a GMP change
Where ICH Q7 Sits in the GMP Landscape
ICH Q7, “Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients,” governs the substance itself — its synthesis, purification, and packaging up to the point it is shipped to a finished-dosage manufacturer. That is a distinct scope from 21 CFR Part 211, which governs the finished pharmaceutical: the tablet, capsule, or injectable made from the API plus excipients. A single supply chain typically runs both regimes in sequence, and an inspector reviewing a finished-product deviation will frequently trace it back to an API lot record governed by Q7, not 211.
Q7 was finalized by ICH in 2000 and has since been adopted, directly or by close incorporation, across FDA guidance, EU GMP Part II, and the PIC/S GMP Guide — which is why an API site can face a US, EU, and PIC/S-member inspection against essentially the same expectations rather than three unrelated rulebooks.
The Increasing-GMP Principle and API Starting Materials
Q7 introduces the concept that GMP rigor increases as a synthetic route approaches the finished API — full formal GMP does not apply to every step back to the first reagent purchased. Instead, the manufacturer defines an “API starting material”: a raw material, intermediate, or API itself that is incorporated as a significant structural fragment into the final API structure. From that defined point forward, full Q7 controls — validated process steps, formal change control, complete batch documentation, qualified equipment — apply. Steps upstream of it are expected to follow sound chemical manufacturing and quality practice, but not the complete Q7 documentation burden.
Choosing the starting material is a judgment call the manufacturer makes and the regulator evaluates, not a fixed rule; picking it too late in the route to avoid GMP burden on genuinely critical steps is a recurring inspection finding.
Impurity Control and Process Understanding Under Q7 and Q11
Q7’s laboratory-control section requires impurity profiling as a routine part of API release testing, and ICH Q11 builds directly on it by describing how a manufacturer develops and justifies a drug-substance control strategy — including which impurities warrant routine batch testing versus periodic or skip-lot verification, based on demonstrated process capability and fate-and-purge understanding accumulated during development.
The APIC “How to Do It” Guide as Practical Interpretation
The Active Pharmaceutical Ingredients Committee (APIC), part of CEFIC, publishes a widely used clause-by-clause interpretive guide to Q7 — informally the “How to Do It” guide. It is industry-authored practical commentary, not an ICH or regulatory document, and SPEQ presents it that way: useful for translating Q7’s principles into site procedures, never a substitute for the guideline itself or for a site’s own regulatory interpretation.
Common Inspection Findings
Recurring API-GMP citations include a starting-material rationale that cannot be defended on scientific grounds, retrospective rather than prospective validation of early process steps once they turn out to be quality-critical, incomplete assessment of how upstream impurities carry forward or are purged through later steps, and site documentation that mixes Q7 and Part 211 terminology in ways that blur which regime a given record is actually satisfying. SPEQ frames this as an interpretation of common findings, not a citation of any single regulator’s enforcement statistics.
FREQUENTLY ASKED
Is ICH Q7 legally binding on its own?
Q7 is harmonized ICH guidance. It becomes enforceable through each regulator’s own GMP framework — FDA guidance, EU GMP Part II, and the PIC/S GMP Guide all incorporate it — rather than functioning as a standalone statute.
How is Q7 different from 21 CFR 211?
211 governs the finished pharmaceutical dosage form; Q7 governs the active substance manufactured before formulation. They apply to different unit operations on the same overall supply chain.
What counts as an API starting material?
The raw material, intermediate, or API incorporated as a significant structural fragment into the API, at the point the manufacturer proposes — and the regulator accepts — as where full Q7 GMP begins to apply.
Does Q7 cover biotechnology-derived APIs?
Q7’s main body is written for chemically synthesized APIs. It notes that cell-culture and fermentation processes need additional controls, which related biotechnology guidance such as ICH Q5A addresses.